The Epidemiological Impact of Carbapenemase-Producing and Multidrug-Resistant Bacteria in Northern Morocco: Findings from a Year-Long Observational Study - Scorecard - MDSpire

The Epidemiological Impact of Carbapenemase-Producing and Multidrug-Resistant Bacteria in Northern Morocco: Findings from a Year-Long Observational Study

  • By

  • Kawtar EL Harrak

  • Ikram AL Faqir

  • EL Mehdi EL Ghorba

  • Reda Amrani Souhli

  • Nouhaila Chahid

  • Moussaab Arbai

  • Majda El-Hassouni

  • Fadila Bousgheiri

  • Adil Najdi

  • Karima Rissoul

  • March 14, 2026

  • 0 min

Share

Clinical Scorecard: The Epidemiological Impact of Carbapenemase-Producing and Multidrug-Resistant Bacteria in Northern Morocco: Findings from a Year-Long Observational Study

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationPatients in Northern Morocco, particularly in hospital settings
Care Setting

Key Highlights

  • bloodstream_infections_percentage

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Consider including specific antibiotics that may still be effective.

          Clinical Best Practices

          • education

          References

          Original Source(s)

          The Epidemiological Impact of Carbapenemase-Producing and Multidrug-Resistant Bacteria in Northern Morocco: Findings from a Year-Long Observational Study

          • by Kawtar EL Harrak, Ikram AL Faqir, EL Mehdi EL Ghorba, Reda Amrani Souhli, Nouhaila Chahid, Moussaab Arbai, Majda El-Hassouni, Fadila Bousgheiri, Adil Najdi, Karima Rissoul

          • March 14, 2026

          Related Content

          Connecting the Diagnostic Dots in HIES

          Clinical case report highlights how classic features of STAT3 hyper-IgE syndrome can be routinely missed in pediatric practice

          Mandatory Training Modules Deserve a Harder Look

          A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.

          Reassessing Empirical Use of Vancomycin in Pediatric Patients in Areas with Low MRSA Incidence: A Study of Necessity and Overprescription